FDA approves Precigen's PRGN-3006 Research New Drug (IND) Application
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Precigen, aof intrexon's wholly ownedcompany,(http:// signed a new licensing agreement with Ziopharm in October, however, Precigen announced thatFDA(http://has approved its prGN-3006 researchnew drug(http://(IND) applicationPRGN-3006
PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T cell (CAR-T) therapy for the treatment of recurrent or refractory acute myeloid leukemia (AML) and high-risk bone marrow hyperplasia syndrome (MDS)PRGN-3006 UltraCAR-T is a multigene CAR-T cell therapy that uses the Sleeping Beauty Platform (SB system) to express chimeric antigen receptors, membrane binding interleukin-15 (mbIL15), and control switches for recurrent or refractory AML and higher risk MDSthis phase 1 clinical dose increase study will assess the safety and maximum tolerable dose of PRGN-3006 UltraCAR-T and will be conducted in collaboration with the Moffitt Cancer Center
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
